• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于 BNT162b2 mRNA COVID-19 疫苗批次相关疑似不良事件的报告:丹麦和瑞典的结果比较。

Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden.

机构信息

LIVA, Rosenvængets Allé 6A, DK-2100 Copenhagen, Denmark.

Innometric, Bavnehøjvej 5, Hellum, DK-9520 Skørping, Denmark.

出版信息

Medicina (Kaunas). 2024 Aug 19;60(8):1343. doi: 10.3390/medicina60081343.

DOI:10.3390/medicina60081343
PMID:39202624
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11356762/
Abstract

: An unexpected batch-dependent safety signal for the BNT162b2 mRNA COVID-19 vaccine was recently identified in a nationwide study from Denmark, but the generalizability of this finding is unknown. Therefore, we compared batch-dependent rates of suspected adverse events (SAEs) reported to national authorities in Denmark and Sweden. : SAE and vaccine batch data were received from national authorities in Denmark and Sweden, and analyses of heterogeneity in the relationship between numbers of vaccine doses and SAEs per batch were performed, along with comparison of SAE rates and severities for batches that were shared between the two countries. : Significant batch-dependent heterogeneity was found in the number of SAEs per 1000 doses for both countries, with batches associated with high SAE rates detected in the early phase of the vaccination campaign and positive correlations observed between the two countries for the severity of SAEs from vaccine batches that they shared. Mild SAEs predominated in the batches used in the early part of the vaccination roll-out, where markedly higher SAE rates per 1000 doses in Denmark for the batches that were shared between the two countries suggested that a large proportion of these SAEs were under-reported in Sweden. : The batch-dependent safety signal observed in Denmark and now confirmed in Sweden suggests that early commercial batches of BNT162b2 may have differed from those used later on, and these preliminary and hypothesis-generating results warrant further study.

摘要

在丹麦进行的一项全国性研究中,最近发现了一种针对 BNT162b2 mRNA COVID-19 疫苗的意外批次相关的安全性信号,但这一发现的普遍性尚不清楚。因此,我们比较了丹麦和瑞典向国家当局报告的与批次相关的疑似不良事件(SAE)的发生率。

SAE 和疫苗批次数据来自丹麦和瑞典的国家当局,并对疫苗剂量与每批 SAE 数量之间的关系进行了异质性分析,并比较了两国共享批次的 SAE 发生率和严重程度。

两国每 1000 剂疫苗的 SAE 数量均存在显著的批次相关异质性,高 SAE 发生率的批次出现在疫苗接种运动的早期阶段,而且两国之间观察到疫苗批次的 SAE 严重程度呈正相关,两国共享的疫苗批次。在疫苗接种推广的早期阶段,轻度 SAE 占主导地位,两国共享的批次中,丹麦每 1000 剂疫苗的 SAE 率明显较高,这表明瑞典对这些 SAE 的报告率明显较低。

在丹麦观察到的、现在在瑞典得到证实的与批次相关的安全性信号表明,BNT162b2 的早期商业批次可能与后来使用的批次不同,这些初步的和产生假设的结果需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ec/11356762/272f475f545b/medicina-60-01343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ec/11356762/7104d5378171/medicina-60-01343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ec/11356762/272f475f545b/medicina-60-01343-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ec/11356762/7104d5378171/medicina-60-01343-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d7ec/11356762/272f475f545b/medicina-60-01343-g002.jpg

相似文献

1
Reports of Batch-Dependent Suspected Adverse Events of the BNT162b2 mRNA COVID-19 Vaccine: Comparison of Results from Denmark and Sweden.关于 BNT162b2 mRNA COVID-19 疫苗批次相关疑似不良事件的报告:丹麦和瑞典的结果比较。
Medicina (Kaunas). 2024 Aug 19;60(8):1343. doi: 10.3390/medicina60081343.
2
Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.一种自我扩增 RNA COVID-19 疫苗(ARCT-154)与 BNT162b2 mRNA COVID-19 疫苗加强针的免疫原性和安全性:一项双盲、多中心、随机、对照、3 期、非劣效性试验。
Lancet Infect Dis. 2024 Apr;24(4):351-360. doi: 10.1016/S1473-3099(23)00650-3. Epub 2023 Dec 20.
3
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.接种 BNT162b2、ChAdOx1 nCoV-19 和 Ad26.COV2.S 疫苗后的心血管、神经和肺部事件:欧洲数据分析。
J Autoimmun. 2021 Dec;125:102742. doi: 10.1016/j.jaut.2021.102742. Epub 2021 Oct 26.
4
Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study.ChAdOx1-S 和 BNT162b2 或 mRNA-1273 疫苗异源初免和加强接种的安全性:全国队列研究。
BMJ. 2022 Jul 13;378:e070483. doi: 10.1136/bmj-2022-070483.
5
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries.在 3 个北欧国家分析 AZD1222、BNT162b2 和 mRNA-1273 新冠疫苗接种后的血栓栓塞和血小板减少事件。
JAMA Netw Open. 2022 Jun 1;5(6):e2217375. doi: 10.1001/jamanetworkopen.2022.17375.
6
Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.香港接种 mRNA(BNT162b2)和灭活(科兴)SARS-CoV-2 疫苗后特殊关注的不良事件和死亡率:一项回顾性研究。
PLoS Med. 2022 Jun 21;19(6):e1004018. doi: 10.1371/journal.pmed.1004018. eCollection 2022 Jun.
7
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years old.一项评估 BNT162b2 新冠疫苗加强针(第三针)与 20 价肺炎球菌结合疫苗联合用于≥65 岁成年人的安全性、耐受性和免疫原性的随机试验。
Vaccine. 2023 Jun 23;41(28):4190-4198. doi: 10.1016/j.vaccine.2023.05.002. Epub 2023 May 8.
8
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.SARS-CoV-2 疫苗接种与 2300 万居民的北欧队列研究中的心肌炎。
JAMA Cardiol. 2022 Jun 1;7(6):600-612. doi: 10.1001/jamacardio.2022.0583.
9
Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.美国关于 COVID-19 疫苗接种后发生 Guillain-Barré 综合征的报告。
JAMA Netw Open. 2023 Feb 1;6(2):e2253845. doi: 10.1001/jamanetworkopen.2022.53845.
10
Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.mRNA COVID-19 疫苗接种后的心肌炎和/或心包炎风险:BNT162b2 和 mRNA-1273 疫苗的加拿大头对头比较。
Vaccine. 2022 Jul 30;40(32):4663-4671. doi: 10.1016/j.vaccine.2022.05.048. Epub 2022 May 25.

引用本文的文献

1
What Lessons can Be Learned From the Management of the COVID-19 Pandemic?从新冠疫情管理中可以吸取哪些教训?
Int J Public Health. 2025 May 30;70:1607727. doi: 10.3389/ijph.2025.1607727. eCollection 2025.
2
Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study.急性 COVID 疫苗接种后综合征中靶向 G 蛋白偶联受体和 RAS 相关分子的自身抗体:一项回顾性病例系列研究。
Biomedicines. 2024 Dec 15;12(12):2852. doi: 10.3390/biomedicines12122852.

本文引用的文献

1
Reports of COVID-19 Vaccine Adverse Events in Predominantly Republican vs Democratic States.主要为共和党和民主党州的 COVID-19 疫苗不良事件报告。
JAMA Netw Open. 2024 Mar 4;7(3):e244177. doi: 10.1001/jamanetworkopen.2024.4177.
2
The mRNA-LNP vaccines - the good, the bad and the ugly?mRNA-LNP 疫苗——好、坏、丑?
Front Immunol. 2024 Feb 8;15:1336906. doi: 10.3389/fimmu.2024.1336906. eCollection 2024.
3
Gene-based COVID-19 vaccines: Australian perspectives in a corporate and global context.基于基因的新冠疫苗:企业与全球背景下的澳大利亚视角
Pathol Res Pract. 2024 Jan;253:155030. doi: 10.1016/j.prp.2023.155030. Epub 2023 Dec 12.
4
Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine.BNT162b2 mRNA新冠疫苗的批次依赖性安全性。
Eur J Clin Invest. 2023 Dec;53(12):e14102. doi: 10.1111/eci.14102. Epub 2023 Oct 13.
5
Unexpected vaginal bleeding and COVID-19 vaccination in nonmenstruating women.非经期女性的意外阴道出血与 COVID-19 疫苗接种。
Sci Adv. 2023 Sep 22;9(38):eadg1391. doi: 10.1126/sciadv.adg1391.
6
Preventive Pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance.预防药物警戒学:通过个体患者筛选和产品剂量水平监测,及时、精准地预防不良事件。
Pharm Res. 2023 Sep;40(9):2103-2106. doi: 10.1007/s11095-023-03548-3. Epub 2023 Jun 22.
7
Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine.BNT162b2 mRNA新冠疫苗的批次依赖性安全性。
Eur J Clin Invest. 2023 Aug;53(8):e13998. doi: 10.1111/eci.13998. Epub 2023 Apr 9.
8
Sources of bias in observational studies of covid-19 vaccine effectiveness.新冠病毒 19 疫苗有效性观察性研究中的偏倚来源。
J Eval Clin Pract. 2024 Feb;30(1):30-36. doi: 10.1111/jep.13839. Epub 2023 Mar 26.
9
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency.瑞典药品管理局对新冠疫苗安全性监测的优化
Drug Saf. 2023 Mar;46(3):319-321. doi: 10.1007/s40264-023-01275-7. Epub 2023 Feb 14.
10
Censorship and Suppression of Covid-19 Heterodoxy: Tactics and Counter-Tactics.对新冠疫情异见的审查与压制:策略与应对策略
Minerva. 2022 Nov 1:1-27. doi: 10.1007/s11024-022-09479-4.